ATE286384T1 - Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan - Google Patents

Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan

Info

Publication number
ATE286384T1
ATE286384T1 AT97117479T AT97117479T ATE286384T1 AT E286384 T1 ATE286384 T1 AT E286384T1 AT 97117479 T AT97117479 T AT 97117479T AT 97117479 T AT97117479 T AT 97117479T AT E286384 T1 ATE286384 T1 AT E286384T1
Authority
AT
Austria
Prior art keywords
glycosaminoglycan
sustained release
release formulation
formulation containing
containing collagen
Prior art date
Application number
AT97117479T
Other languages
English (en)
Inventor
Norimasa Koseki
Akihiko Sano
Original Assignee
Sumitomo Pharma
Koken Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma, Koken Kk filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE286384T1 publication Critical patent/ATE286384T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97117479T 1996-10-09 1997-10-09 Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan ATE286384T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26880196 1996-10-09

Publications (1)

Publication Number Publication Date
ATE286384T1 true ATE286384T1 (de) 2005-01-15

Family

ID=17463462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97117479T ATE286384T1 (de) 1996-10-09 1997-10-09 Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan

Country Status (9)

Country Link
US (1) US5922356A (de)
EP (1) EP0838219B1 (de)
KR (1) KR100577041B1 (de)
AT (1) ATE286384T1 (de)
AU (1) AU727049B2 (de)
CA (1) CA2217134A1 (de)
DE (1) DE69732170T2 (de)
ES (1) ES2236775T3 (de)
NZ (1) NZ328898A (de)

Families Citing this family (347)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US20040018226A1 (en) * 1999-02-25 2004-01-29 Wnek Gary E. Electroprocessing of materials useful in drug delivery and cell encapsulation
US20020081732A1 (en) * 2000-10-18 2002-06-27 Bowlin Gary L. Electroprocessing in drug delivery and cell encapsulation
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
WO2000064481A1 (en) * 1999-04-22 2000-11-02 Eidgenössische Technische Hochschule (ETH) Controlled release of growth factors from heparin containing matrices
MXPA01010692A (es) * 1999-04-22 2004-09-06 Univ Zuerich Matrices de proteina modificadas para ingenieria de tejidos o liberacion controlada.
CA2457162A1 (en) * 2000-09-01 2002-03-07 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed fibrin-based matrices and tissues
CA2325842C (en) 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
EP1443944A1 (de) * 2001-11-12 2004-08-11 Johannes Reinmüller Pharmazeutische anwendungen von hyaluronsäure-präparaten
WO2003066083A1 (en) * 2002-02-04 2003-08-14 Sumitomo Pharmaceuticals Company, Limited Preparations for treating bone fracture or bone loss or elevating bone density
EP1572933A4 (de) 2002-02-13 2007-09-05 Univ Duke Modulation der immunantwort durch polypeptide als antwort auf nichtpeptidischen bindungsstress
EP2301573A1 (de) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen gegen Krebs und Infektionskrankheiten und Anwendungsverfahren dafür
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
FR2862878B1 (fr) * 2003-11-27 2006-03-24 Sofradim Production Substrat metallique revetu d'une composition de collagene et de polysaccharides, procede et applications
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1866319B1 (de) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl-nukleoside und analoga
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
AU2007225139A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
CN101535304A (zh) 2006-09-21 2009-09-16 埃迪威克斯生物科学公司 丝氨酸水解酶抑制剂
BRPI0715579A2 (pt) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
BRPI0808089A2 (pt) * 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
ES2693948T3 (es) 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009079712A1 (en) 2007-12-24 2009-07-02 The University Of Queensland Coating method
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009097660A1 (en) * 2008-02-07 2009-08-13 The University Of Queensland Patch production
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
AU2009249600A1 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics Holding S.A. Niacin and NSAID for combination therapy
CA2760680A1 (en) * 2008-05-23 2009-11-26 The University Of Queensland Analyte detection by microneedle patch with analyte selective reagents
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
WO2010014134A1 (en) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
CN102325563A (zh) 2008-12-22 2012-01-18 昆士兰大学 贴剂制备
EP2376524B1 (de) 2008-12-31 2017-03-15 Cypralis Limited Derivate von cyclosporin a
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
PL2401267T3 (pl) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
KR101748891B1 (ko) * 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
SG175748A1 (en) 2009-04-22 2011-12-29 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
PE20120810A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
AR076363A1 (es) 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2655883T5 (es) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio
EP2467144A1 (de) 2009-07-24 2012-06-27 ViroLogik GmbH Kombination aus proteasehemmern und antihepatitismedikation zur behandlung von hepatitis
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2515654A4 (de) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc Neue ergolinanaloga
AU2010339460A1 (en) 2009-12-30 2012-07-19 Scynexis Inc. Cyclosporine analogues
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2531197B1 (de) 2010-02-05 2017-05-17 Tragara Pharmaceuticals, Inc. Feste formen von makrocyclischen kinasehemmern
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2542542B1 (de) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Isotopisch angereicherte arylsulfonamid-ccr3-antagonisten
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
WO2011116161A2 (en) 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Arylsulfonamide ccr3 antagonists
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
CA2801003A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
NZ604018A (en) 2010-06-07 2015-02-27 Novomedix Llc Furanyl compounds and the use thereof
WO2012006677A1 (en) 2010-07-14 2012-01-19 The University Of Queensland Patch applying apparatus
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
MX347927B (es) 2010-07-19 2017-05-19 Summa Health System Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2611502A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosin-a3-rezeptormodulierende verbindungen und ihre verwendung
EP2611812A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridin- und thienopyrimidinverbindungen sowie verfahren zu ihrer verwendung
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US8912324B2 (en) 2010-09-01 2014-12-16 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611792B1 (de) 2010-09-01 2017-02-01 Ambit Biosciences Corporation Hydrobromid salze einer pyrazolylaminoquinazolin
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
ES2644236T3 (es) 2010-12-14 2017-11-28 National University Of Singapore Anticuerpo humano monoclonal con especificidad para el virus Dengue serotipo 1 E proteína y usos de la misma
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
EP2683383B1 (de) 2011-03-11 2017-11-29 Celgene Corporation Verwendung von 3-(5-amino-2-methyl-4-oxochinazolin-3 (4h) -yl) piperidin-2-6-dion bei der behandlung von immunbedingten und entzündlichen erkrankungen
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691384B1 (de) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituierte aralkylamino- und heteroaralkylamino)-pyrimidinyl- und 1,3,5-triazinyl-benzimidazoles, sie enthaltende pharmazeutische zusammensetzungen und diese verbindungen zur verwendung bei der behandlung proliferativer erkrankungen
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
EP2723735A4 (de) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc Neue fluorergolin-analoga
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
EP2751093A1 (de) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2765927B1 (de) 2011-10-12 2021-02-24 Vaxxas Pty Limited Abgabegerät
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
MY167575A (en) 2011-10-14 2018-09-20 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
AU2012355982A1 (en) 2011-12-19 2014-07-10 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2852604B1 (de) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
TR201904785T4 (tr) 2012-08-09 2019-05-21 Celgene Corp (S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
CN114939119A (zh) 2012-08-09 2022-08-26 细胞基因公司 免疫相关和炎性疾病的治疗
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
US9156799B2 (en) 2012-09-07 2015-10-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (de) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-verbrückten nukleoside für hcv-infektion
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
EP2920195A1 (de) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alaninester eines rp-nukleosidanalogons
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
AU2013352106B2 (en) 2012-11-30 2018-04-26 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
EP3718557A3 (de) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylat-cyclase-rezeptoragonist sp-333 zur verwendung in der darmreinigung
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP2981542B1 (de) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluor-nukleoside zur behandlung von hcv
ES2834638T3 (es) 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (de) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
EP3083654A1 (de) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or-nukleoside zur behandlung von hcv
WO2015183346A2 (en) 2014-01-31 2015-12-03 Washington University Imaging and treatment of pathophysiologic conditions by cerenkov radiation
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CA3175724C (en) 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
TWI705967B (zh) 2014-03-20 2020-10-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3142649B1 (de) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Behandlung der komplikationen von chronischer lebererkrankung mit caspase-inhibitor emricasan
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
US9974870B2 (en) 2014-06-09 2018-05-22 Washington University Compositions and methods for treatment and imaging using nanoparticles
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
MY186839A (en) 2014-06-19 2021-08-25 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
ES2830392T3 (es) 2014-07-23 2021-06-03 Ohio State Innovation Foundation Métodos y composiciones relacionados con fragmentos de anticuerpo que se unen a la glicoproteína 72 asociada a tumores (TAG-72)
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
JP2017526713A (ja) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR102331856B1 (ko) 2014-10-21 2021-11-29 다케다 야쿠힌 고교 가부시키가이샤 결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
EP3209658A1 (de) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoidderivate und verfahren zur verwendung
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
US11147954B2 (en) 2015-02-02 2021-10-19 Vaxxas Pty Limited Microprojection array applicator and method
HK1252245A1 (zh) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
WO2017044866A2 (en) 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11103259B2 (en) 2015-09-18 2021-08-31 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
US20180264244A1 (en) 2015-09-28 2018-09-20 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof
US10112953B2 (en) 2015-09-30 2018-10-30 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
IL284874B2 (en) 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP4455145A3 (de) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP3397251A1 (de) 2015-12-31 2018-11-07 Conatus Pharmaceuticals, Inc. Verfahren zur verwendung von caspase-hemmern bei der behandlung von lebererkrankungen
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
EP3399978B1 (de) 2016-01-08 2020-09-09 Celgene Corporation Antiproliferative verbindungen und deren pharmazeutische zusammensetzungen und verwendungen
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
ES2912921T3 (es) 2016-04-29 2022-05-30 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11339142B2 (en) 2016-09-07 2022-05-24 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
MX390121B (es) 2016-09-19 2025-03-20 Mei Pharma Inc Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
RS61745B1 (sr) 2016-11-03 2021-05-31 Kura Oncology Inc Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR102003179B1 (ko) 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
EP3601326A4 (de) 2017-03-20 2020-12-16 The Broad Institute, Inc. Verbindungen und verfahren zur regulierung der insulinsekretion
CA3057978A1 (en) 2017-03-27 2018-10-04 The Regents Of The University Of California Compositions and method of treating cancer
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
EP3601290B1 (de) 2017-03-29 2021-11-24 Siteone Therapeutics, Inc. 11,13-modifizierte saxitoxine zur behandlung von schmerzen
AU2018241251B2 (en) 2017-03-31 2024-06-27 Vaxxas Pty Limited Device and method for coating surfaces
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MA49141A (fr) 2017-05-19 2020-03-25 Nflection Therapeutics Inc Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
CA3063535A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
JP2020522504A (ja) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ 多環式化合物およびそれらの用途
EP3639010B1 (de) 2017-06-13 2025-08-06 Vaxxas Pty Limited Qualitätskontrolle von substratbeschichtungen
EP4548954A3 (de) 2017-08-04 2025-07-30 Vaxxas Pty Limited Kompakter hoher mechanischer energiespeicher und aktuator mit geringer auslösekraft für die abgabe von mikroprojektions-array-patches (map)
MX2020001207A (es) 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
CA3076920A1 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California Immunomodulatory oligosaccharides
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020003421A (es) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
EP3806856A1 (de) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2-inhibitorverbindungen, zusammensetzungen und verfahren im zusammenhang damit
EP3814327A1 (de) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorphenoxy)pentansäure-derivate und verwandte verbindungen als caspase-inhibitoren zur behandlung kardiovaskulärer erkrankungen
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3873469A2 (de) 2018-11-01 2021-09-08 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
CA3120351A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
EP4233834A3 (de) 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Aryl-anilin- und heteroaryl-anilinverbindungen zur behandlung von muttermalen
EP3898609A1 (de) 2018-12-19 2021-10-27 Shy Therapeutics LLC Mit der ras-superfamilie interagierende verbindungen zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020181165A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP4003314B1 (de) 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Funktionalisierte langkettige kohlenwasserstoffmono- und -dicarbonsäuren zur vorbeugung oder behandlung von krankheiten
US12319967B2 (en) 2019-08-21 2025-06-03 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
WO2022103988A2 (en) 2020-11-11 2022-05-19 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding rna overlapping the lck gene that regulates prostate cancer cell growth
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
EP4034236A1 (de) 2019-09-26 2022-08-03 Abionyx Pharma SA Verbindungen zur behandlung von lebererkrankungen
IL291398B2 (en) 2019-10-01 2025-05-01 Molecular Skin Therapeutics Inc Benzoxazinone compounds as dual inhibitors of KLK5/7
EP4157271A1 (de) 2020-05-29 2023-04-05 Boulder Bioscience LLC Verfahren zur verbesserten endovaskulären thrombektomie mit 3,3'-diindolylmethan
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4149471A4 (de) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. Isochinolinderivate, verfahren zur synthese und verwendungen davon
CN116368139A (zh) 2020-08-14 2023-06-30 赛特温治疗公司 用于治疗疼痛的nav1.7的非水合酮类抑制剂
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
AU2022368836A1 (en) 2021-10-22 2024-05-02 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
MX2024005822A (es) 2021-11-30 2024-05-28 Kura Oncology Inc Compuestos macrociclicos con actividad inhibidora de la farnesiltransferasa.
JP2025501308A (ja) 2022-01-03 2025-01-17 ライラック セラピューティクス， インク． 非環式チオールプロドラッグ
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
AU2023241822A1 (en) 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AR129053A1 (es) 2022-04-14 2024-07-10 Bristol Myers Squibb Co Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
KR20250006012A (ko) 2022-04-15 2025-01-10 셀진 코포레이션 약물에 대한 림프종의 반응성을 예측하는 방법 및 림프종을 치료하는 방법
GEAP202516637A (en) 2022-04-25 2025-03-25 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
AU2023265665A1 (en) 2022-05-05 2024-10-10 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
EP4593826A1 (de) 2022-09-30 2025-08-06 Boulder Bioscience LLC Zusammensetzungen mit 3,3'-diindolylmethan zur behandlung von nichthämorrhagischen verletzungen des geschlossenen kopfes
EP4605084A2 (de) 2022-10-18 2025-08-27 Eluciderm Inc. 2-substituierte 3,4a, 5,7,8, 8a-hexahydro-4h-thiopeno [4,3-d]pyrimidin-4-one zur wundbehandlung
EP4608838A1 (de) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocyclus mit pyridonverbindungen
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
EP4626864A1 (de) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Lineare heteroaryldiamid-ire1/xbp1s-aktivatoren
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024145662A1 (en) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
TW202448485A (zh) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
IL327069A (en) 2023-09-27 2026-05-01 Isosterix Inc Mist inhibitors
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025085878A1 (en) 2023-10-20 2025-04-24 Altay Therapeutics, Inc. N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
WO2025102082A1 (en) 2023-11-10 2025-05-15 Altay Therapeutics, Inc. Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025221809A1 (en) 2024-04-16 2025-10-23 Eluciderm Inc. 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
TW202604501A (zh) 2024-05-17 2026-02-01 美商賽特溫治療公司 用於治療疼痛之ＮＡｖ１．８之經取代之環烷基及雜環烷基抑制劑
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
JPS6097918A (ja) * 1983-11-01 1985-05-31 Sumitomo Chem Co Ltd インタ−フエロン持続性製剤
JPS6084213A (ja) * 1983-10-14 1985-05-13 Sumitomo Chem Co Ltd 徐放性消炎鎮痛製剤
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
JPS6089418A (ja) * 1983-10-20 1985-05-20 Sumitomo Chem Co Ltd 徐放性制癌剤
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
JPS60126217A (ja) * 1983-12-14 1985-07-05 Sumitomo Chem Co Ltd 長期徐放性製剤
JPS62186298A (ja) * 1986-02-12 1987-08-14 ヤマハ株式会社 電子楽器の自動伴奏装置
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
JPH021287A (ja) * 1986-12-25 1990-01-05 Terumo Corp 生体適合性材料、これを用いた医用材料およびマイクロカプセルならびにそれらの製法
EP0326151B1 (de) * 1988-01-29 1993-06-16 Sumitomo Pharmaceuticals Company, Limited Verbesserte Formulierungen mit kontrollierter Abgabe
JP2641755B2 (ja) * 1988-01-29 1997-08-20 住友製薬株式会社 コントロールリリース製剤
ATE89766T1 (de) * 1989-01-31 1993-06-15 Coletica Verwendung von atelokollagen und polyholosiden, z.b. glykosaminoglykan enthaltende loesungen zur herstellung von mikrokapseln die danach erhaltenen mikrokapseln und verfahren zu deren herstellung; praeparate, welche nahrungsstoffe, medikamente oder kosmetische zusammensetzungen enthalten.
DE69202351T2 (de) * 1991-02-14 1996-02-29 Balsells Joan C Schwingungsdämpfende Lagervorrichtung.
EP0503583A1 (de) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Erythropoietin enthaltendes Arzneimittel mit verzögerter Wirkstofffreigabe
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5693341A (en) * 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents

Also Published As

Publication number Publication date
EP0838219A1 (de) 1998-04-29
DE69732170D1 (de) 2005-02-10
AU3990797A (en) 1998-04-23
ES2236775T3 (es) 2005-07-16
DE69732170T2 (de) 2005-12-15
EP0838219B1 (de) 2005-01-05
KR100577041B1 (ko) 2006-12-04
US5922356A (en) 1999-07-13
KR19980032708A (ko) 1998-07-25
CA2217134A1 (en) 1998-04-09
NZ328898A (en) 1999-02-25
AU727049B2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
DE69530926D1 (de) Mittel zur förderung des haarwachstums
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
ATE452640T1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
DE69329448D1 (de) Pharmazeutisches Produkt
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
DE60022683D1 (de) Nervenschutzmittel
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
FI950165A7 (fi) Ihon läpäisevä terapeuttinen järjestelmä, jossa vaikuttavana aineena o n 17-beta-estradioli (vedetön)
ITRM960364A0 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
AU3401093A (en) Therapeutic agent for threatened abortion
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
EP0914826A4 (de) Mittel zur beschleunigung der wundheilung
PT972521E (pt) Composicao farmaceutica contendo estimuladores de interferao gama
EP0826374A3 (de) Pharmazeutische Zusammensetzung zur Verhütung und/oder Behandlung von Krankheiten mit Bezug auf Apoptose
GB9505082D0 (en) Medicament
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties